拓爾思(300229.SZ):462.5167萬股限售股將解禁
格隆匯12月9日丨拓爾思(300229.SZ)公佈,此次解除限售股份為公司2018年發行股份購買資產並配套募集資金時向江南、宋鋼、王亞強、李春保發行股份購買廣州科韻大數據技術有限公司(現更名為“廣州拓爾思大數據有限公司”,“科韻大數據”“廣州拓爾思”“標的公司”)35.43%股權的部分股份。
此次解除限售股份數量為462.5167萬股,佔截至2021年12月6日公司總股本714,757,183股比例為0.6471%。此次解除限售的股份全部處於質押狀態,待解除質押後方可上市流通。此次解除限售股份實際可上市流通股份數量為0股。
此次解除限售股份可上市流通日期為2021年12月15日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.